ArQule Shares Outstanding 2006-2019 | ARQL

ArQule shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ArQule Annual Shares Outstanding
(Millions of Shares)
2018 99
2017 75
2016 70
2015 63
2014 63
2013 62
2012 60
2011 53
2010 45
2009 44
2008 44
2007 40
2006 36
2005 35
ArQule Quarterly Shares Outstanding
(Millions of Shares)
Q1 2019 109
Q4 2018 99
Q3 2018 107
Q2 2018 101
Q1 2018 87
Q4 2017 75
Q3 2017 72
Q2 2017 71
Q1 2017 71
Q4 2016 70
Q3 2016 71
Q2 2016 71
Q1 2016 65
Q4 2015 63
Q3 2015 63
Q2 2015 63
Q1 2015 63
Q4 2014 63
Q3 2014 63
Q2 2014 63
Q1 2014 63
Q4 2013 62
Q3 2013 63
Q2 2013 62
Q1 2013 62
Q4 2012 60
Q3 2012 62
Q2 2012 61
Q1 2012 54
Q4 2011 53
Q3 2011 54
Q2 2011 53
Q1 2011 51
Q4 2010 45
Q3 2010 45
Q2 2010 45
Q1 2010 44
Q4 2009 44
Q3 2009 44
Q2 2009 44
Q1 2009 44
Q4 2008 44
Q3 2008 44
Q2 2008 44
Q1 2008 44
Q4 2007 40
Q3 2007 44
Q2 2007 37
Q1 2007 36
Q4 2006 36
Q3 2006 36
Q2 2006 35
Q1 2006 35
Q4 2005 35
Q3 2005 35
Q2 2005 35
Q1 2005 33
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.896B $0.026B
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $53.030B 33.88
Takeda Pharmaceutical (TAK) Japan $26.701B 7.84
Grifols (GRFS) Spain $13.249B 16.76
Sage Therapeutics (SAGE) United States $8.913B 0.00
Ionis Pharmaceuticals (IONS) United States $8.713B 19.05
Neurocrine Biosciences (NBIX) United States $7.661B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.390B 10.13
Catalent (CTLT) United States $7.241B 29.06
Nektar Therapeutics (NKTR) United States $5.822B 9.49
Tilray (TLRY) Canada $3.793B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.518B 12.34
FibroGen (FGEN) United States $3.505B 0.00
United Therapeutics (UTHR) United States $3.427B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.448B 368.86
PTC Therapeutics (PTCT) United States $2.338B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.052B 7.39
Pacira Pharmaceuticals (PCRX) United States $1.803B 87.32
Xencor (XNCR) United States $1.764B 48.17
Portola Pharmaceuticals (PTLA) United States $1.754B 0.00
USANA Health Sciences (USNA) United States $1.738B 15.10
Tricida (TCDA) United States $1.694B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.688B 23.07
Zogenix (ZGNX) United States $1.661B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.604B 0.00
Madrigal Pharmaceuticals (MDGL) United States $1.504B 0.00
Aerie Pharmaceuticals (AERI) United States $1.457B 0.00
Heron Therapeutics (HRTX) United States $1.398B 0.00
Esperion Therapeutics (ESPR) United States $1.324B 0.00
Turning Point Therapeutics (TPTX) United States $1.245B 0.00
Corcept Therapeutics (CORT) United States $1.190B 16.98
Radius Health (RDUS) United States $1.014B 0.00
Endo (ENDP) Ireland $0.916B 1.47
Theravance Biopharma (TBPH) Cayman Islands $0.895B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.834B 0.00
CannTrust Holdings (CTST) Canada $0.683B 0.00
Organogenesis Holdings (ORGO) United States $0.669B 0.00
Odonate Therapeutics (ODT) United States $0.669B 0.00
Aptorum Group (APM) China $0.649B 0.00
TherapeuticsMD (TXMD) United States $0.589B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.562B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.521B 0.00
Translate Bio (TBIO) United States $0.511B 0.00
Dermira (DERM) United States $0.506B 0.00
ChemoCentryx (CCXI) United States $0.484B 0.00
Akebia Therapeutics (AKBA) United States $0.483B 0.00
GlycoMimetics (GLYC) United States $0.483B 0.00
Siga Technologies (SIGA) United States $0.443B 1.04
Corbus Pharmaceuticals Holdings (CRBP) United States $0.442B 0.00
Flexion Therapeutics (FLXN) United States $0.414B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.409B 20.65
Collegium Pharmaceutical (COLL) United States $0.402B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.391B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.374B 0.00
Karyopharm Therapeutics (KPTI) United States $0.348B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.344B 0.00
KalVista Pharmaceuticals (KALV) United States $0.343B 0.00
Forty Seven (FTSV) United States $0.331B 0.00
TCR2 Therapeutics (TCRR) United States $0.327B 0.00
CASI Pharmaceuticals (CASI) United States $0.301B 0.00
ImmunoGen (IMGN) United States $0.296B 0.00
Harpoon Therapeutics (HARP) United States $0.290B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.285B 0.00
OptiNose (OPTN) United States $0.285B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.263B 0.00
Molecular Templates (MTEM) United States $0.262B 0.00
Dova Pharmaceuticals (DOVA) United States $0.261B 0.00
Xeris Pharmaceuticals (XERS) United States $0.259B 0.00
Concert Pharmaceuticals (CNCE) United States $0.256B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.240B 0.00
Aratana Therapeutics (PETX) United States $0.234B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.225B 0.00
Lannett Co Inc (LCI) United States $0.205B 1.99
Calithera Biosciences (CALA) United States $0.204B 0.00
Recro Pharma (REPH) United States $0.201B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.198B 0.00
Aclaris Therapeutics (ACRS) United States $0.193B 0.00
Ocular Therapeutix (OCUL) United States $0.187B 0.00
IMV INC (IMV) Canada $0.187B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.186B 0.00
Aldeyra Therapeutics (ALDX) United States $0.180B 0.00
Nature's Sunshine Products (NATR) United States $0.177B 57.31
Taiwan Liposome, Unsponsored ADR (TLC) Taiwan $0.175B 0.00
MEI Pharma (MEIP) United States $0.175B 0.00
Minerva Neurosciences (NERV) United States $0.172B 0.00
Galectin Therapeutics (GALT) United States $0.168B 0.00
Ardelyx (ARDX) United States $0.167B 0.00
Opexa Therapeutics (ACER) United States $0.166B 0.00
Bio Blast Pharma (ENLV) Israel $0.164B 0.00
Redhill Biopharma (RDHL) Israel $0.158B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.146B 0.00
Jounce Therapeutics (JNCE) United States $0.146B 0.00
Majesco Entertainment (PTE) United States $0.144B 0.00
Neon Therapeutics (NTGN) United States $0.136B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.129B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.119B 0.00
Tyme Technologies (TYME) United States $0.116B 0.00
Aquestive Therapeutics (AQST) United States $0.105B 0.00
Iterum Therapeutics (ITRM) Ireland $0.103B 0.00
MediWound (MDWD) Israel $0.102B 0.00
Champions Oncology (CSBR) United States $0.101B 0.00
Avenue Therapeutics (ATXI) United States $0.099B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.097B 69.44
Natural Alternatives (NAII) United States $0.092B 9.15
Infinity Pharmaceuticals (INFI) United States $0.091B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.089B 0.00
Mast Therapeutics (SVRA) United States $0.088B 0.00
Cardiome Pharma (CORV) Canada $0.088B 0.00
Capnia (SLNO) United States $0.087B 0.00
DURECT (DRRX) United States $0.085B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.082B 0.00
Nivalis Therapeutics (ALPN) United States $0.080B 0.00
Adherex Technologies (FENC) United States $0.080B 0.00
Otonomy (OTIC) United States $0.078B 0.00
Genocea Biosciences (GNCA) United States $0.074B 0.00
China SXT Pharmaceuticals (SXTC) China $0.071B 0.00
Novan (NOVN) United States $0.070B 0.00
Neos Therapeutics (NEOS) United States $0.068B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.066B 0.00
SCYNEXIS (SCYX) United States $0.062B 0.00
ElectroCore (ECOR) United States $0.058B 0.00
CTI BioPharma (CTIC) United States $0.053B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.052B 0.00
Zafgen (ZFGN) United States $0.051B 0.00
ProNAi Therapeutics (SRRA) Canada $0.049B 0.00
AIT Therapeutics (AITB) Israel $0.046B 0.00
Forward Pharma (FWP) Denmark $0.046B 0.00
KemPharm (KMPH) United States $0.045B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.043B 0.00
Mannatechorporated (MTEX) United States $0.040B 0.00
Bio-Path Holdings (BPTH) United States $0.040B 0.00
Lipocine (LPCN) United States $0.040B 0.00
BioLineRx (BLRX) Israel $0.038B 0.00
ContraFect (CFRX) United States $0.037B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.037B 0.00
PharmAthene (ALT) United States $0.035B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
Heat Biologics (HTBX) United States $0.025B 0.00
Citius Pharmaceuticals (CTXR) United States $0.023B 0.00
Biomerica (BMRA) United States $0.023B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.022B 0.00
Onconova Therapeutics (ONTX) United States $0.021B 0.00
Pain Therapeutics (SAVA) United States $0.021B 0.00
Regulus Therapeutics (RGLS) United States $0.020B 0.00
Melinta Therapeutics (MLNT) United States $0.020B 0.00
PRECISION THERAPEUTICS INC (POAI) United States $0.018B 0.00
Cyanotech (CYAN) United States $0.018B 0.00
Achieve Life Sciences (ACHV) United States $0.017B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.017B 1.38
HANCOCK JAFFE (HJLI) United States $0.016B 0.00
ESSA Pharma (EPIX) Canada $0.014B 0.00
Shineco (TYHT) China $0.014B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.014B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.013B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.011B 1.82
Eyegate Pharmaceuticals (EYEG) United States $0.011B 0.00
VAXART, INC (VXRT) United States $0.011B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.010B 0.00
Trillium Therapeutics (TRIL) Canada $0.010B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.010B 0.00
Jaguar Animal Health (JAGX) United States $0.009B 0.00
RXi Pharmaceuticals (PHIO) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.009B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.008B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.005B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.005B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00